RxDoctor Payments Data

Mansi Shah, DO

Rheumatology · Shreveport, LANPI 1003090663

Payments from drug & device makers

$4,337in general payments, 2019–2025

Across 245 payments — averaging $17.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • Pfizer$518
  • Novartis$518
  • GSK$357
  • UCB, Inc.$298
  • Johnson & Johnson$167
  • plus $934 from 17 others

What the payments were for

  • Food & beverage$4,17296%
  • Education$1413%
  • Other$251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,337 in reported general payments places this provider in the 30th percentile of 88 rheumatology providers in Louisiana.

See all rheumatology providers in Louisiana

Medicare billing

Part B allowed, 2024
$112,529
Medicare patients
267
Services billed
2,680

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab71$505,393
Humira PenAdalimumab56$398,422
Cimzia (2 Pack)Certolizumab Pegol24$135,058
Cosentyx Sensoready PenSecukinumab13$112,907
KevzaraSarilumab24$107,362
SavellaMilnacipran Hcl17$13,716
Leflunomide211$9,082
Hydroxychloroquine Sulfate344$8,769
MitigareColchicine23$6,612
Colchicine106$5,889
Gabapentin359$2,961
MethotrexateMethotrexate Sodium185$2,930
Febuxostat27$2,533
Diclofenac Sodium54$2,190
Duloxetine Hcl179$1,913

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Cimzia (2 Pack)$298$135,05824 claims
SanofiKevzara$32$107,36224 claims
AbbVieSavella$58$13,71617 claims
Hikma Pharmaceuticals USAMitigare$23$6,61223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 88 rheumatology providers in Louisiana.

Other rheumatology in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →